The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce...

Area of Science:

• Oncology
• Cancer Research
• Epigenetics

Background:

• Pancreatic cancer (PC) has a dismal 5-year survival rate (<5%) despite advances in diagnosis and treatment.
• Novel therapeutic strategies are crucial to improve survival and quality of life for PC patients.
• Epigenetic therapies, including histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi), have shown efficacy in various human cancers.

Purpose of the Study:

• To evaluate the efficacy of epigenetic therapeutic agents as potential treatments for pancreatic cancer.
• To assess the effects of HDACi (SAHA) and DNMTi (5-AZA-dc) on pancreatic cancer cell proliferation, death, and DNA synthesis in vitro.
• To investigate the in vivo efficacy of these agents in delaying tumor growth.

Main Methods:

• In vitro studies using MiaPaCa2 cells treated with SAHA and/or 5-AZA-dc.
• In vivo studies assessing tumor growth delay in response to epigenetic agent treatment.
• Analysis of cell proliferation, cell death, DNA synthesis, and p21WAF1 expression.

Main Results:

• SAHA and 5-AZA-dc decreased cell proliferation in MiaPaCa2 cells.
• SAHA, with or without 5-AZA-dc, induced higher cell death and lower DNA synthesis compared to 5-AZA-dc alone.
• Combination treatment with SAHA and 5-AZA-dc significantly increased p21WAF1 expression, causing G1 arrest and delaying tumor growth in vivo.

Conclusions:

• Epigenetic modifier drugs show potential for pancreatic cancer management.
• Combination therapy with SAHA and 5-AZA-dc demonstrates anti-proliferative and cell death-inducing effects.
• These agents may be particularly useful for the chemoprevention of pancreatic cancer when combined with other chemotherapeutics.